Working... Menu
Trial record 45 of 169 for:    pertuzumab

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01875666
Recruitment Status : Active, not recruiting
First Posted : June 12, 2013
Last Update Posted : November 2, 2018
Genentech, Inc.
Susan G. Komen Breast Cancer Foundation
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : December 2016
  Estimated Study Completion Date : March 2019